Additive Manufacturing

Search documents
3D Systems Receives $7.65 Million Contract Award from U.S. Air Force for Advanced Metal Printing System
Globenewswire· 2025-08-26 20:05
Two-year contract award for Large-format Metal 3D Printer Advanced Technology DemonstratorSupports development of large-scale industrial metal AM print capabilities for high-speed flight applicationsAward is an extension of an existing program to demonstrate key technologies needed for 3D printing large, high-temperature metal structures associated with high-speed flight operating environments ROCK HILL, S.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE: DDD), a leading U.S.-based additive man ...
3D Systems Announces Chief Financial Officer Transition
Globenewswire· 2025-08-20 20:15
3D Systems’ Executive Vice President, Phyllis Nordstrom to Serve as Interim Chief Financial Officer ROCK HILL, S.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE: DDD) announced that Jeffrey D. Creech is stepping down as the company’s Chief Financial Officer, effective August 29, 2025, to accept a new career opportunity. Phyllis Nordstrom, 3D Systems’ Executive Vice President, Chief Administrative Officer, has been appointed Interim CFO, effective August 29, 2025. “I want to thank Jeff for his ...
Top 3D Printing Stocks for Higher Returns and Portfolio Growth
ZACKS· 2025-08-19 17:31
Industry Overview - 3D Printing, or additive manufacturing, is a transformative technology that creates physical objects from digital designs by layering materials with high precision, significantly changing product design and manufacturing since the 1980s [1] - The technology is gaining traction across various sectors, including healthcare, aerospace, automotive, and consumer goods, due to its ability to produce complex shapes and reduce supply chain costs [3][4] Market Growth - The global 3D Printing market is projected to grow from $24.61 billion in 2024 to $29.29 billion in 2025, and is expected to reach $134.6 billion by 2034, with a CAGR of 18.52% [6] - The healthcare 3D Printing market is anticipated to increase from $1.66 billion in 2024 to $1.96 billion by the end of the year, with projections to exceed $8.71 billion by 2034, reflecting a CAGR of 18% [5] Regional Insights - North America currently leads the 3D Printing market with over 35% share, followed closely by Asia Pacific at 30%, with strong growth expected in the U.S. market at a CAGR of 19.18% from 2025 to 2034 [7] Key Players - Xometry, Proto Labs Inc., and Stratasys, Ltd. are recognized as leaders in the 3D Printing space, capitalizing on the technology's advantages in cost, customization, precision, and sustainability [2] - GE Aerospace has made significant investments in additive manufacturing, enhancing fuel efficiency in its engines by 10% to 15% through 3D-printed components [11][12][13] - PTC's Creo software is designed to optimize product development in 3D printing, offering advanced capabilities for manufacturers [15][16] - Carpenter Technology has developed its additive manufacturing capabilities through strategic acquisitions and is recognized for its versatile metal powder production [17][18][19] - Proto Labs is noted for its rapid prototyping and on-demand production capabilities, generating approximately $84 million in revenue from its 3D Printing services in 2024 [22] - 3D Systems provides a wide range of 3D printing solutions and has made strides in digital dentistry and bioprinting, collaborating on projects with NASA [23][24][25][26]
Stratasys(SSYS) - 2025 Q2 - Earnings Call Transcript
2025-08-13 13:30
Financial Data and Key Metrics Changes - Consolidated revenue for Q2 2025 was $138.1 million, slightly higher than Q2 2024, reflecting ongoing customer deferral of major capital spending due to market uncertainty [21] - GAAP gross margin was 43.1%, down from 43.8% in the same period last year, while non-GAAP gross margin was 47.7%, down from 49% [22] - GAAP operating loss for the quarter was $16.6 million, an improvement from a loss of $26 million in the same period last year, while non-GAAP operating income was $1.1 million compared to a loss of $3.2 million [23][24] - Cash flow used in operating activities was $1.1 million, an improvement from $2.4 million in Q2 2024, with an expectation of positive operating cash flow for the full year 2025 [24] Business Line Data and Key Metrics Changes - Product revenue was $94.8 million, up from $93.6 million in the same period last year, while service revenue was $43.3 million, down from $44.4 million [21] - Within product revenue, system revenue increased to $30.6 million from $29 million, and consumables revenue was $64.2 million, slightly down from $64.6 million but up 2.6% sequentially [21] Market Data and Key Metrics Changes - Customer engagement remains strong despite macroeconomic challenges, with ongoing investment in R&D and new technology offerings [6][20] - The company launched the North American Stratasys Tooling Center to help manufacturers validate and scale additive manufacturing applications [9] Company Strategy and Development Direction - The long-term growth strategy focuses on capturing opportunities in high-growth sectors influenced by megatrends such as supply chain localization and sustainability [7][8] - The company emphasizes innovation and execution, aiming to solidify its leadership in digital manufacturing as market dynamics stabilize [6][30] Management's Comments on Operating Environment and Future Outlook - Management noted that customer spending remains challenged, impacting near-term business views, but the long-term outlook remains positive [19][20] - The return to normalized capital spending has been delayed, with expectations for significant opportunities in production applications to close potentially moving into 2026 [25][26] Other Important Information - The company ended the quarter with $254.6 million in cash and equivalents, bolstered by a $120 million investment [25] - New material offerings include P3 Silicon 25A, designed for the Stratasys Origin DLP platform, enhancing capabilities in industrial 3D printing [16] Q&A Session Summary Question: Can you clarify which specific verticals or regions are seeing the most pronounced slowdown or delays? - Management clarified that there is no slowdown, only delays, particularly in larger production application deals which have longer sales cycles [32][34] Question: What assumptions are baked into the fourth quarter adjusted EBITDA margin? - The guidance for Q4 is largely based on cost monitoring and reductions, with no large deals factored into the model [39][40] Question: What is impacting the gross margin? - Gross margin changes are attributed to sales mix changes, inventory absorption issues, and tariff impacts [43][46] Question: Can you elaborate on the Nexa asset acquisition? - The acquisition included valuable IP and R&D knowledge, positioning the company stronger in key use cases [56][59] Question: Do you anticipate additional partnerships with other vehicle OEMs? - Management expressed optimism about expanding partnerships, leveraging proven use cases from collaborations with GM and Toyota [72][74]
Stratasys(SSYS) - 2025 Q2 - Earnings Call Presentation
2025-08-13 12:30
Financial Performance - Q2 2025 revenue was $138.1 million, a 0.1% increase year-over-year[26, 48] - GAAP gross margin was 43.1% in Q2 2025, a decrease of 0.7% compared to Q2 2024's 43.8%[30, 48] - Non-GAAP gross margin was 47.7% in Q2 2025, a decrease of 1.3% compared to Q2 2024's 49.0%[30, 48] - GAAP operating loss improved to $16.6 million in Q2 2025 from $26.0 million in Q2 2024[36, 48] - Non-GAAP operating income was $1.1 million in Q2 2025, compared to a loss of $3.2 million in Q2 2024[36, 48] - GAAP net loss improved to $16.7 million in Q2 2025 from $25.7 million in Q2 2024[36, 48] - Non-GAAP net income was $2.2 million in Q2 2025, compared to a loss of $3.0 million in Q2 2024[36, 48] Balance Sheet and Cash Flow - The company's cash and cash equivalents and short-term deposits were $254.6 million in Q2 2025[39] - Net working capital was $448.8 million in Q2 2025[39] - Cash flow from operating activities was negative $1.1 million in Q2 2025[38] Outlook - The company expects full-year 2025 revenue between $550 million and $560 million[42] - The company expects full-year 2025 non-GAAP gross margins between 46.7% and 47.0%[42] - The company expects full-year 2025 non-GAAP operating expenses between $248 million and $251 million[42]
3D Systems(DDD) - 2025 Q2 - Earnings Call Presentation
2025-08-12 12:30
August 12, 2025 Second Quarter 2025 Financial Results Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Mick McCloskey Vice President, Treasury & Investor Relations To participate via phone, please dial: 1-201-689-8345 4 2 Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private S ...
Novanta (NOVT) - 2025 Q2 - Earnings Call Transcript
2025-08-05 15:02
Financial Data and Key Metrics Changes - Revenue reached $241 million, representing reported revenue growth of 2% and organic revenue declines of 2% [7] - Adjusted gross margins held at 46% and adjusted EBITDA margin was 22%, both in line with expectations [8][29] - Non-GAAP adjusted earnings per share was $0.76, up 4% versus the prior year [29] - Operating cash flow for the quarter was $15 million compared to $41 million in the prior year, primarily driven by timing of tax payments and increased inventory purchases [29][30] Business Line Data and Key Metrics Changes - New product revenue grew by over 50% year over year, with a vitality index climbing to 21% of total sales [33] - Advanced surgery business experienced 17% growth year over year, driven by strong patient procedural growth rates [35] - Robotics and automation business unit revenue was up nearly 16% year over year, with a book to bill ratio of 1.05 [34] - Precision medicine business saw a 13% decline in sales year over year, but grew 10% sequentially [35] Market Data and Key Metrics Changes - Sales to medical device markets remained strong, driving sustained double-digit growth in advanced surgery [11] - Sales to industrial capital equipment saw declines year over year, but revenue has stabilized and bookings are rising at a double-digit pace [18] - Total China sales were up 15% year over year, despite challenges related to tariffs [80] Company Strategy and Development Direction - Long-term growth strategy focuses on markets with secular tailwinds such as precision and AI-driven robotics, minimally invasive surgery, and precision medicine [10] - The company aims to expand its portfolio into high-growth areas, increasing recurring consumables revenue to approximately 15% of sales [11] - The acquisition of Keon Technologies is expected to enhance the company's capabilities in RFID and AI-enhanced cloud-based software [30][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $50 million of incremental new product revenue for 2025, mainly due to strong outlook for next-generation medical devices [12] - The company is optimistic about the growth in physical AI applications, expecting sales to double in 2026 versus 2025 [15] - Management acknowledged the impact of tariffs but indicated that mitigation strategies are in place, with a focus on regional manufacturing [37][40] Other Important Information - The company expects full-year 2025 GAAP revenue to be approximately $970 million to $985 million, representing overall revenue growth of 2% to 4% [41] - Adjusted EBITDA for the full year of 2025 is expected to be $225 million to $230 million, or approximately a 23% EBITDA margin [42] - The company has a strong balance sheet and credit facility, positioning it well for future acquisitions [47] Q&A Session Summary Question: Can you break down your revenue guidance? - The full year guidance indicates reported organic growth will likely be down 1% to up 1% [53] Question: What is the FX implied impact for benefit? - The FX impact is expected to carry forward from the second quarter [55] Question: What are the biggest drivers of organic growth in 2026? - Key drivers include advanced surgery product ramps, physical AI applications, and strong design wins [60][64] Question: Have we seen the low point for the year in industrial and precision medicine? - Management believes the industrial business has reached its bottom and will improve sequentially [72] Question: What is the status of the $35 million held up due to tariffs? - This amount is factored into guidance, and recovery is not assumed yet [79] Question: Can you elaborate on the warehouse robotics win? - The technology involves sensing and fast, safe reactions, essential for advanced warehouse automation [90]
Velo3D to Announce Second Quarter 2025 Results on August 06, 2025
Prnewswire· 2025-08-01 13:00
Core Viewpoint - Velo3D, Inc. is set to release its second quarter 2025 financial results on August 6, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Velo3D is a leading US-based metal 3D printing technology company that specializes in additive manufacturing (AM) [4]. - The company has developed solutions that overcome the limitations of legacy metal AM, allowing for the design and production of high-value metal parts [5]. - Velo3D's technology is utilized in various industries, including space exploration, aviation, power generation, energy, and semiconductors, enabling the creation of mission-critical components [5]. Technology and Innovation - The company's integrated solution includes Flow print preparation software, the Sapphire family of printers, and the Assure quality control system, all powered by Velo3D's Intelligent Fusion manufacturing process [5]. - Velo3D has been recognized as one of Fast Company's Most Innovative Companies for 2023, highlighting its impact on the industry [5].
Materialise(MTLS) - 2025 Q2 - Earnings Call Transcript
2025-07-24 13:30
Financial Data and Key Metrics Changes - Total consolidated revenue decreased year over year by 5.8% to €64.8 million, despite strong performance in the Medical segment [20][23] - Gross profit margin increased to 58.3%, reflecting changes in revenue mix and optimization of production costs [20][31] - Adjusted EBIT for the quarter amounted to €3.1 million, showing a strong increase compared to prior quarters [20][25] - Net result for the quarter was a profit of €0.2 million, impacted by unfavorable exchange rate fluctuations [20][33] - Free cash flow was positive, leading to a net cash position of €63 million at the end of Q2, an increase of €2 million since the beginning of the year [20][35] Business Line Data and Key Metrics Changes - Medical segment achieved high double-digit growth, with revenue increasing by almost 17% this quarter [20][26] - Software segment revenue decreased by 12% to €9.9 million, partly due to the transition to a recurring revenue model and macroeconomic pressures [20][27] - Manufacturing segment revenue declined by almost 25% compared to the same period last year, realizing quarterly revenue of €22.1 million [20][29] Market Data and Key Metrics Changes - Materialise Medical accounted for 51% of total revenue, Materialise Software for 15%, and Materialise Manufacturing for 34% in Q2 [23] - The U.S. market continued to face challenges, impacting sales volumes in the Software segment [27][61] Company Strategy and Development Direction - The company is focusing on mass personalization in the medical business, expanding into new markets such as respiratory [7][8] - A pilot collaboration with Johnson & Johnson aims to advance the adoption of surgical planning solutions in the respiratory market [11] - The company is engaging with the defense sector to enhance regional defense capabilities, which is expected to open new opportunities [15][16] Management Comments on Operating Environment and Future Outlook - Management anticipates that geopolitical volatility and macroeconomic uncertainty may intensify, impacting the business climate for the remainder of the year [37] - Revenue guidance for the full year has been slightly reduced from €270 million - €285 million to €265 million - €280 million [38] - Despite the lower revenue outlook, management remains confident in the fundamentals of the business and the potential for structural cost efficiencies [38] Other Important Information - The company continues to invest in R&D, with over €11 million spent in the quarter, primarily in the Medical segment [32] - A restructuring in the manufacturing division has been implemented to manage costs amid revenue pressures [19][30] Q&A Session Summary Question: Can you quantify the opportunity in the respiratory market? - Management indicated that the respiratory market is new and still developing, with revenue impact not expected until next year [44][45] Question: What is the purpose of the €20 million debt taken out during the quarter? - This debt is part of an earlier agreement for a €50 million facility, intended for CapEx or M&A investments in the future [47][49] Question: What drove the strong gross margins despite lower revenues? - The strong gross margins were attributed to a combination of mix effects and the ability to reduce production costs in both medical and manufacturing segments [50] Question: Will the medical segment continue to see double-digit growth? - Management expressed confidence that the medical segment will continue to grow, with ongoing investments in new markets [58] Question: What parameters were used for the revised top-line guidance? - The revised guidance was based on a detailed exercise considering various business lines and market conditions, rather than a single parameter [60][62]
Northann Corp. Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
Globenewswire· 2025-07-02 21:12
Company Overview - Northann Corp. is a leader in additive manufacturing and 3D printing technologies for the building materials industry, founded in 2022 and headquartered in Fort Lawn, South Carolina [2] - The company offers innovative flooring, decking, and other construction products through its flagship brand, Benchwick [2] - Northann holds a robust portfolio of over 60 granted or pending patents, highlighting its commitment to innovation and sustainability [2] Financial Disclosure - Northann Corp. disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, that the audit opinion contained a going concern qualification from its independent registered public accounting firm [1] - This announcement was made to comply with NYSE American Company Guide Sections 401(h) and 610(b), requiring separate disclosure of such audit opinions [1] - The announcement does not represent any change or amendment to the company's 2024 audited financial statements or its 2024 annual report on Form 10-K [1]